Skip to main content
. 2022 Jun 9:10.2217/fon-2022-0148. doi: 10.2217/fon-2022-0148

Table 1. Demographic and clinical characteristics of included patients.

  n = 112
Age (years), median (range) 62 (24–81)
Sex, n (%)
  – Male
  – Female
47 (42%)
65 (58%)
Cancer type, n (%)
  – NSCLC
  – Breast cancer
  – Genitourinary cancer
  – Malignant mesothelioma
  – SCLC
  – Ovarian cancer
  – Gastrointestinal cancer
80 (71%)
13 (12%)
5 (4%)
5 (4%)
4 (4%)
3 (3%)
2 (2%)
Stage, n (%)
  – Limited
  – Locoregionaly advanced
  – Metastatic
22 (20%)
11 (10%)
79 (70%)
Currently receiving anticancer therapy, n (%)
  – Yes
  – No
98 (88%)
14 (12%)
Anticancer therapy, n (%)
  Chemotherapy alone
    – Age in y, median (range)
    – Male
    – Currently receiving therapy		 26 (23%)
61 (36–76)
12 (46%)
15 (58%)
  Immune checkpoint inhibitors
    – Age, years, median (range)
    – Male
    – Currently receiving therapy		 44 (39%)
63 (24–73)
26 (59%)
42 (95%)
  Targeted therapy (tyrosine kinase inhibitors or endocrine therapy)
    – Age, years, median (range)
    – Male
    – Currently receiving therapy		 42 (38%)
61 (33–81)
9 (21%)
41 (98%)
Currently receiving steroids, n (%)‡
  – No
  – Yes
108 (96%)
4 (4%)
Other immunomodulatory therapy, n (%)§
  – No
  – Yes
111 (99%)
1 (1%)
Type of vaccination received, n (%)†
  – mRNA-based BNT162b2 (Pfizer/BioNTech)
  – mRNA-based mRNA-1273 (Moderna)
109 (97%)
3 (3%)
History of SARS-CoV-2 infection, n (%)#
  – No
  – Yes
99 (88%)
13 (12%)
Positive SARS-CoV-2 IgG antibodies before vaccination, n (%)††
  – No
  – Yes
90 (80%)
22 (20%)
†

All patients received two doses.

‡

Receiving methylprednisolone, dexamethasone or prednisolone not received within cancer treatment regimens.

§

One patient receiving anti-IL-23 therapy for psoriasis.

#

SARS-CoV-2 status was positive at baseline if the patient had clinical or virological evidence of COVID-19 illness either by positive patient history and positive reverse transcriptase-PCR or positive reverse transcriptase-PCR test alone.

††

Patients were considered to have positive SARS-Cov-2 IgG antibodies if the level of anti-SARS-CoV-2 S1 IgG was above the threshold of 175 ng/ml.

NSCLC: Non-small-cell lung cancer; SCLC: Small-cell lung cancer.